

15 Jan 2021 | News

QUOTED. 15 January 2021. Kevin Conroy.

by

Exact Sciences CEO Kevin Conroy discussed the company's future at the annual J.P. Morgan Healthcare Conference

“Colon cancer screening, multi-cancer screening and minimum residual disease testing are the three largest impact areas, and in the US alone, this represents a very large opportunity for growth.” – Kevin Conroy, CEO, Exact Sciences

> Find out more: [JPM 2021: Intuitive Surgical, Accelerate Diagnostics, Siemens Healthineers, Exact Sciences, Renalytix](#)

[Click here](#) for a free trial of *Medtech Insight*